{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:18Z","timestamp":1790409258298,"version":"4.1.0"},"reference-count":13,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25058","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:08:31Z","timestamp":1766527711000},"page":"276-282","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the performance of new daratumumab-specific immunofixation electrophoresis reflex agent and the timing of M-protein measurement"],"prefix":"10.3960","volume":"65","author":[{"given":"Naomi","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"},{"name":"Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,"},{"name":"Graduate School, International University of Health and Welfare, Tokyo, Japan (present affiliation)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurano","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan,"},{"name":"Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dimopoulos MA, Oriol A, Nahi H <i>et al.<\/i> Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375: 1319-1331.","DOI":"10.1056\/NEJMoa1607751"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Palumbo A, Chanan-Khan A, Weisel K <i>et al.<\/i> Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375: 754-766.","DOI":"10.1056\/NEJMoa1606038"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Durie BG, Harousseau JL, Miguel JS <i>et al.<\/i> International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rajkumar SV, Harousseau JL, Durie B <i>et al.<\/i> Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117: 4691-4695.","DOI":"10.1182\/blood-2010-10-299487"},{"key":"5","unstructured":"5 Kumar S, Paiva B, Anderson KC <i>et al.<\/i> International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17: e328-e346."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Liu L, Wertz WJ, Kondisko A, Shurin MR, Wheeler SE. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring. J Appl Lab Med. 2020; 5: 29-40.","DOI":"10.1373\/jalm.2019.029009"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tang F, Malek E, Math S, Schmotzer CL, Beck RC. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab. Am J Clin Pathol. 2018; 150: 121-129.","DOI":"10.1093\/ajcp\/aqy037"},{"key":"8","unstructured":"8 Soda M, Yamaguchi M, Inoue K <i>et al.<\/i> Evaluation of False-Positive Band Disappearance in Immunofixation after Daratumumab Administration and the Effectiveness of \u201cPretreatment of D-Clean\u201d [in Japanese]. Jpn J Lab Med. 2025; 73: 613-616."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 McCudden C, Axel AE, Slaets D <i>et al.<\/i> Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016; 54: 1095-1104.","DOI":"10.1515\/cclm-2015-1031"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Cailon H, Irimia A, Simon JS <i>et al.<\/i> Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed DIRA Test: Hydrashift 2\/4 Daratumumab [abstract]. Blood. 2016; 128: 2063.","DOI":"10.1182\/blood.V128.22.2063.2063"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Baloda V, Shurin MR, Wheeler SE. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab. J Appl Lab Med. 2022; 7: 910-915.","DOI":"10.1093\/jalm\/jfab174"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Xu XS, Moreau P, Usmani SZ <i>et al.<\/i> Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020; 37: 1464-1478.","DOI":"10.1007\/s12325-020-01247-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kim K, Phelps MA. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. Clin Pharmacokinet. 2023; 62: 789-806.","DOI":"10.1007\/s40262-023-01240-8"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25058\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:53Z","timestamp":1766810513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25058\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25058","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25058"}}